Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) is set to present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14 to 16, 2020. The presentation will take place on September 16, 2020, from 10:30 a.m. to 10:50 a.m. ET. A live and archived webcast will be available on their website. The company is focusing on FT218, a once-nightly sodium oxybate formulation, currently undergoing trials for treating narcolepsy. FT218 has received Orphan Drug Designation from the FDA, highlighting its potential superiority over existing treatments.

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the H.C. Wainwright 22^nd Annual Global Investment Conference taking place September 14 – 16, 2020.

Presentation details:
Date:		Wednesday, September 16, 2020
Time:		10:30 a.m. – 10:50 a.m. ET
Webcast:		A live and archived webcast of the presentation will be available at (click here) or on the Company’s website (click here)

In addition, management will be participating in one-on-one meetings with investors who are registered to attend the conference.

About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

About FT218
FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. The Company recently completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.

Contacts:

Investor Contacts Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.com Tim McCarthy LifeSci Advisors, LLC Phone: (212) 915-2564 Email: tim@lifesciadvisors.com Media Contact Patrick Bursey LifeSci Communications, LLC Phone: (646) 970-4688 Email: pbursey@lifescicomms.com

FAQ

What is the date and time of Avadel Pharmaceuticals' presentation at the conference?

Avadel Pharmaceuticals will present on September 16, 2020, from 10:30 a.m. to 10:50 a.m. ET.

Where can I watch the webcast of the Avadel Pharmaceuticals presentation?

The webcast of the Avadel Pharmaceuticals presentation can be viewed live and archived on their website.

What is the focus of Avadel Pharmaceuticals in their recent press release?

The focus of the press release is on FT218, an investigational once-nightly formulation of sodium oxybate for treating narcolepsy.

What designation has FT218 received from the FDA?

FT218 has been granted Orphan Drug Designation by the FDA for the treatment of narcolepsy.

What is the significance of FT218 in the treatment of narcolepsy?

FT218 may offer a clinically superior option to the twice-nightly formulation of sodium oxybate, with potential safety advantages.